INTRODUCTION
Characterization of the molecular defect of deficient proteins can indicate the relation of structure to function of a protein. Hereditary high molecular weight kininogen (HK) deficiency is a rare entity. Williams trait has a molecular defect of C to T transition at nucleotide 586 resulting in a stop codon in exon 5 which prematurely stops biosynthesis of HK after amino acid position 195 (corresponding to position 177 of the mature protein) (1, 2) . Williams trait is associated with an absence of both high and low molecular weight kininogen (LK) in plasma (1, 3) . Alternatively, Fitzgerald trait, the first HK deficient plasma recognized, has absent functional HK activity and 40% normal levels of LK antigen though plasma bradykinin levels were found to be normal (4, 5) .
A cohesive hypothesis has recently been elaborated for the assembly, activation, and physiologic activity of HK and the plasma kallikrein/kinin system (6) . The pivotal protein in the assembly and activation of this system is plasma HK. The plasma kininogens, HK and LK, are multi-domain proteins whose major purpose is to provide the biologically active peptide, bradykinin. However, as part of kinin deliverance, the kininogens have other activities recognized by structure and function analysis. The identical heavy chain of both HK and LK has the ability to bind to cell membranes, inhibit cellular cysteine proteases, and interfere with thrombin activation of protease activated receptor 1 (7) (8) (9) (10) . The unique light chain domain of HK, produced by alternative splicing of the kininogen RNA, has the ability to bind to cell membranes to bring prekallikrein (PK) and factor XI to cell and artificial surfaces for activation (11) (12) (13) . When PK bound to HK assembles on its multiprotein receptor complex on endothelial cells or cell matrix, PK is rapidly activated to kallikrein by the endothelial cell enzyme, For personal use only. on . by guest www.bloodjournal.org From 5 prolylcarboxypeptidase (3, (14) (15) (16) . Since prolylcarboxypeptidase is also an angiotensin II degrading enzyme, the plasma kallikrein-kinin system may counterbalance the renin-angiotensin system (6, (16) (17) (18) . Formed plasma kallikrein liberates bradykinin from HK stimulating nitric oxide synthesis and the residual cleaved HK expresses new anti-proliferative and anti-angiogenic activity (19-21). Thus the plasma kallikrein/kinin system is intimately involved in regulation of vascular biology.
In this report, we examined the plasma and DNA of a 6 year old boy with a cerebral artery thrombosis who was found to have HK deficiency and Fitzgerald trait. These investigations indicate that truncation or frameshift at or before position 480 of the mature HK prevent biosynthesis, processing and/or the secretion of HK into plasma whereas defects in intron 9 of the kininogen gene may result in the absence of synthesis of domain 6 of HK.
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MATERIALS AND METHODS
Case Report. A 6 year old male with no previous medical history and whose parents are first cousins presented with cephalgia and vomiting occurring 10 days after moderate cervical trauma followed by a loss of consciousness and subsequent visual impairment. On computerized axial tomography (CAT) and angiography, the patient had an extensive left vertebral-basilar artery thrombosis and a left vertebral artery dissection. The patient had a prolonged APTT and received 45 ml/kg fresh frozen plasma prior to arteriography and then 10 ml/kg/day for 8 days which resulted in the normalization of the APTT and resolution of neurologic symptoms. On day 8 when the APTT returned to admission values, the patient had a neurologic relapse with new areas of cerebral ischemia on CAT. The patient was anticoagulated with warfarin and 1 month later there was a new headache and vomiting despite warfarin anticoagulation with an international normalized ratio of 2.0. In time, however, there was full neurologic recovery with warfarin therapy for 6 months. There has been no recurrence after 2 years of follow-up. After full informed consent according the Declarations of Helsinki, both plasma and cells for the preparation of DNA were collected from the patient and his immediate family. (3), monoclonal   antibodies HKH14, HKH15, HKL10, HKL13, HKL14, HKL16, HKL12, HKL24, and HKL25   (22) (Table I) , and antisera to the HK domain 5 peptide HKH20 was prepared as previously reported (23) ( Table I) .
Materials
Coagulant assays. Platelet-poor plasma was prepared from blood anticoagulated with 3. Samples were compared against standard curve from pooled normal human plasma diluted in 0.01 M Tris, 0.15 M NaCl, pH 7.4 (TBS). One U/ml HK was defined as that amount of procoagulant activity in a 1/10 dilution of pooled normal plasma.
PK chromogenic activity. Kallikrein activity was measured by utilizing chromogenic substrate H-D-Pro-Phe-Arg-pNA (S-2302, Diapharma Inc., Franklin, OH) as previously reported (24).
Fifty µl normal pooled human plasma for the standard curve or patient plasma samples were acid treated to neutralize plasma protease inhibitors by incubating them with 50 µl of 1/6 N HCl for 15 min at room temperature followed by 50 µl of 0.1M sodium phosphate pH 7.6, 0.15 M NaCl, 1mM EDTA and 50 µl of 0.17 N NaOH. The samples then were diluted in 350 µl of 50 mM Tris, 0.15 M NaCl, pH 7.9 containing 0.1% polyetheylene glycol. Residual PK was determined by taking 50 µl of the acidified, prediluted plasma and incubating it with 50 µl of plasma prekallikrein activator (Chromogenix, Sweden) for 5 min. After incubation, 50 µl of substrate S-2302 (0.4 mM final concentration) was added to the activated plasma and hydrolysis proceeded for 10 min. The reaction was stopped with 100 µl 50% acetic acid. The absorbance was read at 405 nm. The units of kallikrein activity were determined by comparison with that produced by equal amount of pooled normal human plasma. (1, 25) . HK antigen was determined using a polyclonal antibody to the light chain of HK (3). Plasma PK antigen was measured using a monospecific goat polyclonal antiserum as previously reported (25). The amount of HK and PK in plasma was determined by comparison with the known amount of each of these proteins in a characterized pool of normal human plasma (3, 25) . Further studies were performed to sequence kininogen's 2.1 kb intron 9. A deductive PCR sequencing approach was employed starting with a sense primer from the 3' end of exon 9
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(GenBank Accession N o M11528) and an antisense primer from the 5' end of exon 10. The sequential set of sense and antisense primers for sequencing intron 9 are shown in Table II .
Further investigations were performed to sequence the heavy chain of PK from the propositus and his family. PCR was performed to amplify exons 3-6 and 8-10 corresponding to PK's apple domains 1,2 and 4 using the primers and PCR conditions as described by Yu et al.
(27).
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RESULTS
Investigations on plasma HK and PK levels in the patient and family. The propositus had a markedly prolonged APTT with a normal prothrombin time, thrombin time, and clottable fibrinogen (Table III) . On a 1:1 mixing study, there was complete correction of the APTT.
Investigations for most of the established prothrombotic risk factors were negative (Table III) .
The patient had a factor XII coagulant activity of 0.35 U/ml. The patient's prolonged APTT was mostly due to a HK deficiency. The propositus had less than 0.01 U/ml of HK procoagulant activity when compared with pooled normal human plasma (Table IV) . The HK procoagulant activity of his father, mother, and sister on a fresh sample upon presentation in France was 0.38 U/ml, 0.59 U/ml, and 0.65 U/ml, respectively. PK activity and antigen levels also were reduced in the propositus and family members (Table IV) . Some reduction of the PK values could have resulted from lyophilization, shipment to, and resuspension of the plasmas in Ann Arbor, MI.
Reduced HK values in family members were noted in the resuspended lyophilized plasma samples. However, low plasma PK values also have previously been reported in HK deficient patients (28). Reconstitution of their plasma with up to 1.2 U/ml of purified HK did not restore the PK amidolytic or coagulant activity to normal level (data not shown), as previously reported in other HK deficient patients (27). The Apple domains 1, 2, and 4 of the heavy chain of the prekallikrein gene of the propositus and family members were sequenced looking for a polymorphism that might result in interference with HK binding to PK (29,30). In exon 5 that codes for Apple domain 2 of the prekallikrein gene, there was a polymorphism at basepair 180 changing an adenine to guanidine that changed an asparagine to serine in the propositus and other family members (27). 
reduced HK in normal plasma and the patient's family. Interestingly, a strong 92 kDa protein band was also detected in Fitzgerald plasma. Similar findings were seen when Mab HKL10, which is directed to the same epitope on domain 5 as HKL13 (Table I) These investigations provide an opportunity to better understand the molecular basis of HK deficiency. Williams trait is characterized by a premature stop codon at positions 586-588 due to a C to T transition (2) resulting in a shortened mRNA encoding the signal peptide (18 amino acid residues), domain 1 (112 residues), and a portion of domain 2 (65 residues) ( Figure   8 ). Presently it is not known whether the truncated mRNA is actually translated into a protein of 177 residues (after removal of the signal peptide) or whether this truncated form of Williams kininogen is stored and/or rapidly degraded in hepatocytes of the liver, i.e. the major source of human kininogen. Clearly this truncated form is not secreted since no kininogen antigen is detected in Williams plasma. (Figure 8) . Accordingly, the aberrant mRNA encodes a shortened form of HK that comprises 479 residues of the authentic HK sequence covering domains 1 to 4 and most of domain 5, followed by 53 residues of an unrelated sequence starting with a Ser residue such that a mature protein of 532 residues would result after removal of the signal peptide. Because no liver biopsy of the propositus is available to us, questions could not be addressed whether this truncated form of HK is synthesized and properly processed, but accumulated and degraded in hepatocytes. Future studies using the mutated HK cDNA for recombinant expression in mammalian cells should be helpful to answer these questions and to address the possibility that the newly added C-terminus of 53 residues may expose "retention" signals preventing the secretion of the truncated HK form or inducing a rapid intracellular degradation without significant secretion of the aberrant HK protein.
Fitzgerald trait, the first HK deficiency ever reported, (4) differs from other reported HK deficiencies in that a smaller form of HK of 92 kDa (as compared to 120 kDa of normal kininogen) is synthesized, processed, and secreted to be present in its plasma (Figure 8 ).
Antibody mapping studies indicate that the 92 kDa form lacks major portions of domain 6 and that a premature stop may occur between residues 502 and 543, though the precise site has not been determined (Figure 8 
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absence of the synthesis of domain 6 of Fitzgerald's HK is not known. HK protein is produced by an alternative splicing mechanism in exon 10 of the single human kininogen gene (34, 35) .
Each of the intron 9 mutations alone or combined could affect the alternative usage of termination sites and/or change the alternative slicing of the primary transcript of Fitzgerald DNA generating a modified mRNA to produce an altered HK that is eventually targeted to the plasma through the secretory pathways of hepatocytes (34, 35) . This latter possibility is reminiscent of the finding of a Japanese patient lacking HK antigen in the plasma where a partial deletion in intron 7 was proposed as a cause of this defect (36) .
Last, it is of interest that the plasma PK levels in the propositus and his family did not correct to normal upon addition of purified HK in their plasmas. This finding is different from that previously reported in HK-deficient plasmas (28). It is possible that the plasma PK was damaged as result of lyophilization, shipment, and resuspension. However, a polymorphism in Apple domain 2 resulting in a replacement of an asparagine with a serine at amino acid position 124 in the heavy chain of PK was detected in the propositus and his family after sequencing the HK binding regions of Apple domains 1,2 and 4 on PK (29,30). This polymorphism is previously recognized to exist in 30% of the population in the United States (27). It is presently unknown whether this polymorphism influences the plasma level of PK. A single base pair polymorphism was also noted at amino acid 563 of domain 6 of the mature HK that is in the prekallikrein binding region of HK (13) . Two laboratories have shown that amino acids 569-595 on domain 6 are the essential ones to bind PK (31, 32) . Talhe influence of this latter polymorphism to plasma PK levels, if any, is not known. 
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